Antibody Solutions actively engages in partnerships with other companies encompassing discovery or development stages through manufacturing and sales.
Past and present partnerships have taken the form of:
- Collaborative R&D
- OEM supply
- Co-promotion of products or services
Advantages of partnering with Antibody Solutions include:
- Mechanism to more rapidly achieve a goal
- Outsourcing activities a company does not wish to develop internally.
- Attain economies of scale and maximize efficiency
- Gain access to novel technology, innovative approaches and competitive products
Antibody Solutions recognizes the importance of trust and commitment to its partners. We believe partnerships can maximize each company’s strengths to make both firms stronger in the long run, providing both with a competitive advantage. Our proprietary Service Platform makes the management of partnership projects straightforward, accountable, and transparent.
Single Cell Technology, Inc. (SCT) has pioneered a new approach to antibody discovery. Antibodies from secreting cells are rapidly screened against multiple molecules to measure their affinity and specificity and correctly paired mRNA from the cognate light and heavy chains are sequenced by Next Generation Sequencing (NGS). In addition to human and mouse cells, SCT’s AbTHENEUM™ technology can be applied to isolated plasma cells from any host. SCT integrates advances in multiple disciplines, such as wafer fabrication, molecular biology, precision mechanical engineering, nanotechnology, image processing, NGS, and bioinformatics. SCT’s approach substantially decreases the time and investment needed to discover high quality therapeutic and diagnostic antibodies.
Reflexion Pharmaceuticals is composed of a passionate group of scientists engaged in groundbreaking translational research – developing a revolutionary new class of protein-based therapeutics that overcome the limitations of current biologics. By engineering enantiomeric proteins composed entirely of D-peptides, Reflexion is creating new drug entities that are non-immunogenic and inherently resistant to proteolysis, vastly improving pharmacokinetics.Reflexion’s game-changing platform technology allows us to pursue virtually any disease target and shows limitless potential.
Human Transgenic Animal Providers
A fully owned subsidiary of Harbour BioMed, Harbour Antibodies owns two strains of transgenic mice for generating human therapeutic antibodies: (1) H2L2 – mice that generate antibodies comprised of two heavy chains and two light chains with fully human variable regions; and (2) HCAb – mice that generate novel “heavy chain only” antibodies. The HCAb mice enable the development of antibody fragment-based therapeutics such as nanobodies, bi-specific antibodies and CAR-T with favorable drug-like properties.
Ligand’s OmniAb® therapeutic antibody platforms, OmniRat®, OmniFlic®, OmniMouse® and OmniChicken™, produce highly diversified, fully human antibody repertoires optimized in vivo for manufacturability, therapeutic efficacy and reduced immunogenicity – Naturally optimized human antibodies®. The single-license OmniAb offering is the industry’s only with three species and multiple genetic backgrounds to address even the most challenging targets – 3 species, 1 license™.
Trianni, Inc. is a biotech company specializing in antibody discovery technology. TRIANNI’s lead technology, The Trianni Mouse™, is a powerful, next-generation platform enabling efficient generation of fully-human monoclonal antibodies. TRIANNI’s transgenic platform leverages a novel approach to design made possible by advances in DNA synthesis and genomic modification technology making it a best-in-class therapeutic antibody discovery platform.